🇺🇸 FDA
Patent

US 10822427

Anti-CSPG4 fusions with interferon for the treatment of malignancy

granted A61KA61K2039/505A61K38/212

Quick answer

US patent 10822427 (Anti-CSPG4 fusions with interferon for the treatment of malignancy) held by The Regents of the University of California expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/505, A61K38/212, A61K38/215, A61K38/217